返回成功案例
医疗健康

Tem Group has been acquired by Instrumentation Laboratory

The shareholders of Tem Group (TEM) have sold the company to Instrumentation Laboratory (IL). Financial details have not been disclosed.

TEM is a global leader in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the USA, TEM has consistently achieved above market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence-based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.

IL, founded in 1959 and based in Bedford, Massachusetts, is a worldwide developer, manufacturer and distributor of in-vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include critical care systems, hemostasis systems and information management systems. IL is an integral part of the Werfen family of companies which distributes its products by a direct sales force in North America and Werfen organizations around the globe.

"A passion for innovation, leading systems and extensive knowledge in PBM, make TEM a perfect complement to our focus, commitment, and leadership in hemostasis and critical care IVD," said Ramon Benet, CEO at IL. "IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products, to help customers reduce overall hospital costs, while improving patient care."

Oaklins' team in Switzerland advised the seller in this transaction.

我们的服务
交易方

联系交易团队

Dr. Roberto  Tracia

Dr. Roberto Tracia

合伙人
伯尔尼, 瑞士
Oaklins Switzerland
 David  Zürrer

David Zürrer

合伙人
巴塞尔, 瑞士
Oaklins Switzerland

相关交易

Prestige Inhome Care has found a long-term strategic partner
医疗健康

Prestige Inhome Care has found a long-term strategic partner

Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.

更多信息
Cara Care has been acquired by Mahana Therapeutics
私募基金 | 医疗健康 | 科技、媒体及通讯

Cara Care has been acquired by Mahana Therapeutics

Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.

更多信息
Apotheka acquires two pharmacy outlets from Panpharmacy
消费与零售 | 医疗健康

Apotheka acquires two pharmacy outlets from Panpharmacy

In a strategic move that signifies the ongoing consolidation and growth within the Latvian pharmaceutical retail sector, Panpharmacy, the parent company of the leading online pharmacy InternetAptieka.lv, has successfully completed the sale of two of its brick-and-mortar pharmacies to Apotheka. These pharmacies, both situated in the capital city of Riga, will continue to serve customers under the Apotheka brand, marking a seamless transition in ownership and operations.

更多信息